ziyad al aly glp 1 GLP-1 drugs found to reduce the risk of developing addictions Ziyad Al-Aly, MD on X:

Its removal from Category 1 means it is moving into the PCAC review pipeline for a definitive determination rather than remaining in the indefinite "under evaluation" holding pattern

Updated February 2026

All potential benefits therefore must be weighed cautiously, and treatment is undertaken under medical supervision given that safety and efficacy are not yet established by regulatory authorities

The FDA classifies Thrive GLP-1 as a dietary supplement, not a drug

Since vitamin B12 naturally exists mainly in animal foods, vegetarians, especially vegans are at a much higher risk of low levels

doi: 10.1007/s40263-022-00907-3